GlassScriptPhysician profile
Carrie Wynn
NPI 1801250626
$12,445.16
in general payments reported to CMS, 2019-2025
54 companies · $5,875 in 2025
The $5,875 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.01 · 2021: $569 · 2022: $683 · 2023: $1,318 · 2024: $3,986 · 2025: $5,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,550 · Food and Beverage: $5,434 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,550.00 |
| Food and Beverage | $5,433.51 |
| Education | $195.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,073.96 | 2022-2025 | Enhertu, Imfinzi |
| Incyte Corporation | $588.87 | 2022-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $573.95 | 2022-2025 | Reblozyl, Breyanzi, Pomalyst |
| Genzyme Corporation | $392.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $362.03 | 2021-2025 | Iclusig, Livtencity, Ninlaro |
| Astellas Pharma US INC | $318.97 | 2021-2025 | Cresemba, Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $317.27 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $300.06 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $249.33 | 2022-2025 | Venclexta, Polivy |
| Janssen Biotech, INC. | $245.13 | 2024-2025 | Tecvayli, Talvey, Rybrevant |
| Pfizer INC. | $244.31 | 2019-2025 | |
| Seagen INC. | $242.79 | 2022-2023 | Adcetris |
| Abbvie INC. | $187.00 | 2024-2025 | |
| Beigene USA, INC. | $182.99 | 2021-2023 | Brukinsa |
| Gilead Sciences, INC. | $156.00 | 2023-2025 | Trodelvy |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Wynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.